Allogene Therapeutics, Inc. (ALLO) financial analysis and rating
Comparison analysis based on SEC data
|Company Name||Allogene Therapeutics, Inc.|
|Industry (SIC)||2836 - Biological Products, Except Diagnostic Substances|
|Latest report||12/31/2020 (filed 2/25/2021)|
Financial position and performance
|Compared with industry ratios||Change during the year|
|Compared with all industry ratios|
Financial ratios benchmarking
with industry ratios
(28 - Chemicals And Allied Products)
|with all industry ratios|
|ROE (Return on equity), after tax||
|ROA (Return on assets)||
We have conducted a comparative analysis of the balance sheet and the income statement of Allogene Therapeutics, Inc. (hereafter – the "Company") for the year 2020 submitted to the U.S. Securities and Exchange Commission (SEC). The primary business activity of the company is Biological Products, Except Diagnostic Substances (SIC code 2836). During the analysis we have compared the key financial ratios of the company with the average (median) values of those ratios calculated for the specific industry sector and for all industries. The averages are calculated using the data from financial statements for the year 2020 submitted to the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics with the median value, we have made a generalized conclusion about the quality of the financial condition of the company. Calculations and summary conclusions are made in a computerized way using software and methods developed by Consulting financial and analytical company Ankon.
As a result of the analysis of the key financial ratios of the company, we have established the following. The financial condition of Allogene Therapeutics, Inc. in 2020 is much better than the financial condition of half of all companies engaged in the activity "Biological Products, Except Diagnostic Substances"
A similar result was obtained when comparing the financial performance of the Company with the average ratios of all companies. The financial position of Allogene Therapeutics, Inc. is better than that of most listed companies that submit financial statements to the U.S. Securities and Exchange Commission.
Financial position and performance history
Additional data about Allogene Therapeutics, Inc.
|Company||USD ($), in Millions|
|COMPASS THERAPEUTICS, INC.||0||52|
|Kodiak Sciences Inc||0||1,067|
|Aptose Biosciences, Inc.||0||126|
See also all industry leaders
Financial data source and analysis principles
The above is a comparative analysis of the financial position and performance of the company. The comparison is based on official financial statements filed with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) (about 10,000 largest publicly traded companies). The comparison is performed using the eleven key financial ratios (see table above). Company's financial ratios are compared with the median values of ratios of all companies and of companies within the same industry, and also with the quartiles of those ratios. Each ratio value is given a score ranging from -2 and +2 depending on its position relative to the quartiles (-2 – below the first quartile; -1 – between the first and the second quartile; +1 – between the second and the third quartile; +2 – above the third quartile; 0 – the ratio value deviates from the median by no more than 5% of the difference between the median and the quartile closest to the ratio value). To draw a conclusion from the analysis the individual scores are weighted equally to get an overall score ranging from -2 and +2.
|much better (+1 - +2incl)|
|better (from 0.11 to +1incl)|
|about the same (from -0.11incl to +0.11incl)|
|worse (from -1incl to -0.11)|
|much worse (from -2incl to -1)|
Change during the year is calculated by comparing the resulting score of financial position within the industry with the last year's (quarter's) score. The result of the comparison may be as follows:
|improved considerably (positive change of more than 1 point)|
|improved (positive change of less than 1 point)|
|unchanged (little or no change in score, no more than 0.11 points)|
|deteriorated (the score has decreased by less than 1 point during the year)|
|deteriorated considerably (the score has decreased by more than 1 point during the year)|
Please note: The presented analysis does not indicate a poor or good financial position of the company, but gives its description relative to other U.S. businesses. For a detailed financial analysis please use "ReadyRatios Financial Analysis" - load the data into the program>>